Key Takeaways
- • Digital health funding reached $7.4 billion in Q1 2026, the strongest first quarter since the pandemic peak in Q2 2022, up from $5.9 billion in the prior quarter, with 60% of capital concentrated in 19 mega-rounds of $100 million or more.
- • Average deal size climbed to $29.6 million, representing a 46% year-over-year increase, signaling institutional investors' confidence in maturing digital health companies and AI-driven solutions.
- • Healthcare now captures nearly half of all vertical AI spending globally, with AI drug discovery emerging as a primary investment driver alongside increased M&A activity, which surged 47% with 56 deals closed in the quarter.
- • Abbott's $23 billion acquisition of Exact Sciences represents the quarter's largest transaction, underscoring market prioritization of proven commercial adoption and established customer bases over regulatory clearance alone.
- • A critical adoption readiness gap persists: less than 20% of enterprise healthcare data is currently prepared for AI implementation without substantial preprocessing, as legacy EHR and CRM systems were designed for billing and compliance rather than predictive modeling.
Summary
Digital health funding rebounded sharply in Q1 2026, reaching $7.4 billion globally and marking the strongest opening quarter since the sector's pandemic-era peak. This represents a sequential increase of $1.5 billion from the prior quarter and reflects accelerating institutional capital deployment into healthcare AI solutions. According to CB Insights' State of Digital Health Q1'26 report, the capital concentration was notable: 19 mega-rounds—transactions valued at $100 million or more—captured 60% of total quarterly funding, indicating that investor attention increasingly focuses on well-capitalized, later-stage companies with demonstrated traction.
The composition and sizing of deals reveal a maturing market. Average deal size rose to $29.6 million, a 46% year-over-year increase, suggesting that investors are deploying larger checks into fewer, more selective opportunities. Healthcare's share of vertical AI spending has expanded substantially, now representing nearly half of all enterprise AI investment. Within the healthcare AI vertical, drug discovery applications have emerged as a dominant funding thesis, reflecting confidence in computational approaches to pharmaceutical development and the potential for productivity acceleration in R&D workflows.
M&A activity intensified dramatically, with 56 deals closed in Q1 2026—a 47% quarterly jump that signals consolidation in the digital health ecosystem. Abbott's acquisition of Exact Sciences for $23 billion exemplified the market's strategic direction: buyers prioritize companies with established commercial footprints and proven revenue traction over those with novel technology or early regulatory approvals. DeepHealth's $269 million acquisition of Gleamer, driven by the target's 700+ hospital contracts, reinforced this pattern. Conversely, Oxipit—despite achieving world-first autonomous AI certification—experienced limited valuation gains due to minimal 2024 revenue of $27.6 thousand, demonstrating that regulatory achievement alone cannot compensate for absent commercial adoption.
However, structural challenges constrain deployment velocity. Less than 20% of enterprise healthcare data is currently AI-ready without substantial preparation and cleansing. Legacy systems such as EHRs and CRMs were architecturally designed for billing, compliance, and sales tracking rather than predictive modeling, resulting in widespread data quality issues including inconsistent measurement units and non-standardized diagnosis coding. This readiness gap creates both risk and opportunity: implementation failures are common among early AI pilots, yet companies successfully navigating data preparation and deployment command significant acquisition premiums, positioning data infrastructure and operational excellence as critical competitive differentiators in the 2026 digital health market.
The composition and sizing of deals reveal a maturing market. Average deal size rose to $29.6 million, a 46% year-over-year increase, suggesting that investors are deploying larger checks into fewer, more selective opportunities. Healthcare's share of vertical AI spending has expanded substantially, now representing nearly half of all enterprise AI investment. Within the healthcare AI vertical, drug discovery applications have emerged as a dominant funding thesis, reflecting confidence in computational approaches to pharmaceutical development and the potential for productivity acceleration in R&D workflows.
M&A activity intensified dramatically, with 56 deals closed in Q1 2026—a 47% quarterly jump that signals consolidation in the digital health ecosystem. Abbott's acquisition of Exact Sciences for $23 billion exemplified the market's strategic direction: buyers prioritize companies with established commercial footprints and proven revenue traction over those with novel technology or early regulatory approvals. DeepHealth's $269 million acquisition of Gleamer, driven by the target's 700+ hospital contracts, reinforced this pattern. Conversely, Oxipit—despite achieving world-first autonomous AI certification—experienced limited valuation gains due to minimal 2024 revenue of $27.6 thousand, demonstrating that regulatory achievement alone cannot compensate for absent commercial adoption.
However, structural challenges constrain deployment velocity. Less than 20% of enterprise healthcare data is currently AI-ready without substantial preparation and cleansing. Legacy systems such as EHRs and CRMs were architecturally designed for billing, compliance, and sales tracking rather than predictive modeling, resulting in widespread data quality issues including inconsistent measurement units and non-standardized diagnosis coding. This readiness gap creates both risk and opportunity: implementation failures are common among early AI pilots, yet companies successfully navigating data preparation and deployment command significant acquisition premiums, positioning data infrastructure and operational excellence as critical competitive differentiators in the 2026 digital health market.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.